Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome

Blood Adv. 2019 Sep 10;3(17):2664-2667. doi: 10.1182/bloodadvances.2019000465.

¹ Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital.
² Department for BioMedical Research.
³ Department of Rheumatology, Immunology, Allergology, Inselspital, Bern University Hospital.
⁴ Department of Medical Oncology, Inselspital, Bern University Hospital.
⁵ Department of Diagnostic, Interventional and Pediatrics Radiology, Bern University Hospital.
⁶ Institute of Pathology, and.
⁷ Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Abstract

Reduction of APL antibodies by immunoadsorption may be a lifesaving therapy for the management of DAH with high titer of APL antibodies.
Autologous HSCT may be a valid treatment option in patients with primary APS and no response to standard immunosuppressive therapy.